Wedbush Raises Price Target on Apellis Pharmaceuticals to $67 From $55, Sees Increased Probability of Approval for Pegcetacoplan in Geographic Atrophy; Neutral Kept
Wedbush Raises Price Target on Apellis Pharmaceuticals to $67 From $55, Sees Increased Probability of Approval for Pegcetacoplan in Geographic Atrophy; Neutral Kept
Wedbush将Apellis Pharmicals的目标股价从55美元上调至67美元，认为Pegcetacoplan在《地理萎缩》中获得批准的可能性增加；保持中立
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册